Method for preparing liposome osimertinib

The liposome technology wraps osimertinib, which solves the problem of single drug administration routes of osimertinib, realizes the flexibility of multiple drug administration routes and drug targeting, and improves the solubility of osimertinib and stability, meeting the treatment needs of patients with special EGFR mutant lung adenocarcinoma.

CN119015226AInactive Publication Date: 2024-11-26HARBIN MEDICAL UNIVERSITY
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202410970468.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-19
Publication Date
2024-11-26
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing osimertinib drugs are mainly oral, and cannot meet the intrathecal drug injection needs of patients with special EGFR mutant lung adenocarcinoma such as meningeal metastasis, and lack the flexibility of multiple administration routes.

Method used

Osimirtinib is wrapped by liposome technology, and the liposome Osimirtinib is prepared by mixing phospholipids, cholesterol and osimirtinib, and the steps of dissolution, rotary evaporation, ultrasonic oscillation and other steps of anhydrous ethanol are used to prepare liposome Osimirite with high solubility and stability. Tinib suspension, achieving intrathecal, abdominal, local and intravenous administration.

Benefits of technology

It improves the solubility and bioavailability of osimertinib, enhances the targeting of drugs, provides multiple drug delivery routes, enhances the flexibility of treatment, and improves the stability of drugs for easy storage and transportation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015226A_ABST
    Figure CN119015226A_ABST
Patent Text Reader

Abstract

The invention provides a method for preparing liposome osimertinib, and relates to the field of pharmaceutical preparations, and the method comprises the following steps: S1, weighing phospholipid, cholesterol and osimertinib, putting the weighed materials into a centrifuge tube, and uniformly mixing the materials; s2, adding absolute ethyl alcohol into the centrifugal tube, oscillating and uniformly mixing; s3, pouring the dissolved absolute ethyl alcohol solution of phospholipid, cholesterol and osimertinib into an eggplant-shaped bottle, and connecting the eggplant-shaped bottle with a rotary evaporator; s4, drying in a drying oven; s5, adding a PBS solution into the eggplant-shaped bottle; s6, the eggplant-shaped bottle is placed in an ultrasonic cleaner; s7, sucking the supernate into a new centrifugal tube; and S8, filtering the liquid containing the supernatant in the centrifugal tube through a water system filter membrane to obtain the liposome osimertinib. According to the osimertinib tablet, the solubility and the bioavailability of osimertinib are improved; the targeting property of the medicine is enhanced, and the medicine can act on a tumor part more accurately; the drug has low toxic and side effects, and the liposome has better stability and is convenient to store and transport.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of pharmaceutical preparations, and in particular to a method for preparing liposome osimertinib. Background Art

[0002] Osimertinib is a highly effective and selective EGFR mutant inhibitor, mainly used to treat patients with EGFR-positive metastatic non-small cell lung cancer. It is the world's first third-generation EGFR-TKI targeted therapy drug approved for marketing, and has the characteristic of being the only approved first-line treatment indication. The IC50 of osimertinib for exon 19 deleted EGFR, L858R / T790M EGFR and wild-type EGFR are 12.92nM, 11.44nM and 493.8nM, respectively, showing its high selectivity and inhibitory ability. Currently, all osimertinib drugs on the market are oral drugs with a single administration method, which cannot meet the treatment needs of all patients with EGFR mutant lung adenocarcinoma. For example, for patients with EGFR mutant lung adenocarcinoma with meningeal metastasis, clinical guidelines recommend intrathecal injection as the preferred medication method for such patients, but oral osimertinib cannot achieve this goal. Summary of the invention

[0003] The purpose of the present invention is to provide a method for preparing liposome osimertinib to solve the technical problems existing in the prior art.

[0004] In order to achieve the above-mentioned object of the invention, the technical solution adopted by the present invention is:

[0005] A method for preparing liposome osimertinib comprises the following steps: S1: weighing phospholipid, cholesterol and osimertinib, putting them into a centrifuge tube and mixing them evenly; S2: adding anhydrous ethanol into the centrifuge tube, oscillating and mixing, so that the phospholipid, cholesterol and osimertinib are fully dissolved in the anhydrous ethanol; S3: pouring the dissolved anhydrous ethanol solution of phospholipid, cholesterol and osimertinib into an eggplant-shaped bottle, and connecting the eggplant-shaped bottle to a rotary evaporator; S4: after the solution in the eggplant-shaped bottle is fully evaporated, removing the eggplant-shaped bottle from the rotary evaporator, putting it into an oven for drying, and after drying, A homogeneous milky white film is formed at the bottom of the eggplant-shaped bottle; S5: add PBS solution into the eggplant-shaped bottle, and shake the eggplant-shaped bottle to make the milky white film fully contact with the PBS solution; S6: place the eggplant-shaped bottle in an ultrasonic cleaner, and after ultrasonic oscillation, the milky white film on the wall of the eggplant-shaped bottle falls off completely to obtain a milky white solution; S7: remove the solution in the eggplant-shaped bottle, transfer it to a centrifuge tube, take out the centrifuge tube after centrifugation, and absorb the supernatant into a new centrifuge tube; S8: filter the liquid in the centrifuge tube containing the supernatant through a water filter membrane to obtain liposomal osimertinib.

[0006] Furthermore, in the step S1, the amount of the phospholipid is 15 mg, the amount of the cholesterol is 3 mg, and the amount of osimertinib is 3 mg.

[0007] Furthermore, in step S2, the amount of anhydrous ethanol used is 1.5 ml.

[0008] Furthermore, in step S3, rotary evaporation is performed at 37° C. and 80 rpm / min for 30 minutes.

[0009] Furthermore, in step S4, the drying time is 6-8 hours.

[0010] Furthermore, in step S5, the amount of PBS solution used is 3 ml.

[0011] Furthermore, in step S6, the oscillation frequency of the ultrasonic cleaner is 40 KHz, and the oscillation duration is 15 minutes.

[0012] Furthermore, in step S7, centrifugation is performed at 4000 rpm / min for 15 minutes.

[0013] Furthermore, in step S8, the working size of the water filter membrane is 0.22 μm.

[0014] Compared with the prior art, the present invention has the following beneficial effects:

[0015] The present invention prepares an osimertinib suspension by encapsulating osimertinib with liposomes, thereby improving the solubility and bioavailability of osimertinib, increasing the administration routes, and enabling intrathecal administration, intraperitoneal administration, local tumor injection, and intravenous administration, thereby enhancing the targeting of the drug. The liposomes have better stability and are easy to store and transport. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 It is the structural diagram of the present invention under scanning electron microscope. DETAILED DESCRIPTION

[0017] In order to make the content of the present invention more clearly understood, the technical solutions in the embodiments of the present invention will be described clearly and completely below in conjunction with the drawings in the embodiments of the present invention. The same parts are represented by the same figure marks. It should be noted that the words "front", "rear", "left", "right", "up" and "down" used in the following description refer to the directions in the drawings, and the words "inside" and "outside" refer to the directions toward or away from the geometric center of a specific component, respectively.

[0018] like Figure 1 As shown, this embodiment provides a method for preparing liposome osimertinib, comprising the following steps:

[0019] S1: Weigh 15 mg of phospholipids, 3 mg of cholesterol and 3 mg of osimertinib, put them into a centrifuge tube and mix them evenly;

[0020] S2: Add 1.5 ml of anhydrous ethanol into the centrifuge tube and shake to mix thoroughly to dissolve phospholipids, cholesterol and osimertinib in the anhydrous ethanol;

[0021] S3: Pour the dissolved phospholipids, cholesterol and osimertinib anhydrous ethanol solution into an eggplant-shaped bottle, connect the eggplant-shaped bottle to a rotary evaporator, and perform rotary evaporation at 37°C and 80 rpm / min for 30 minutes;

[0022] S4: After the solution in the eggplant-shaped bottle is fully evaporated, the eggplant-shaped bottle is removed from the rotary evaporator and placed in a 37°C oven for drying for 6-8 hours. A homogeneous milky white film is formed at the bottom of the eggplant-shaped bottle;

[0023] S5: Add 3 ml of PBS solution into the eggplant-shaped bottle and shake the bottle to make the milky white film fully contact with the PBS solution;

[0024] S6: placing the eggplant-shaped bottle in an ultrasonic cleaner, and after 15 minutes of 40KHz ultrasonic oscillation, the milky white film on the wall of the eggplant-shaped bottle completely falls off, and a milky white solution is obtained;

[0025] S7: Remove the solution in the eggplant-shaped bottle and transfer it to a centrifuge tube. Centrifuge at 4000 rpm / min for 15 minutes. After centrifugation, take out the centrifuge tube and transfer the supernatant to a new centrifuge tube.

[0026] S8: Filter the liquid in the centrifuge tube containing the supernatant through a 0.22 μm water filter membrane to finally obtain liposome osimertinib with a particle size of less than 220 nm.

[0027] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention shall be included in the protection scope of the present invention.

Claims

1. A method for preparing liposome osimertinib, characterized in that: include: S1: Weigh phospholipids, cholesterol and osimertinib, put them into a centrifuge tube and mix them evenly; S2: Add anhydrous ethanol into the centrifuge tube and shake to mix well so that phospholipids, cholesterol and osimertinib are fully dissolved in the anhydrous ethanol; S3: Pour the dissolved phospholipids, cholesterol and osimertinib anhydrous ethanol solution into an eggplant-shaped bottle, and connect the eggplant-shaped bottle to a rotary evaporator; S4: After the solution in the eggplant-shaped bottle is fully evaporated, the eggplant-shaped bottle is removed from the rotary evaporator and placed in an oven for drying. After drying, a homogeneous milky white film is formed at the bottom of the eggplant-shaped bottle; S5: Add PBS solution into the eggplant-shaped bottle and shake the eggplant-shaped bottle to make the milky white film fully contact with the PBS solution; S6: placing the eggplant-shaped bottle in an ultrasonic cleaner, and after ultrasonic oscillation, the milky white film on the wall of the eggplant-shaped bottle completely falls off to obtain a milky white solution; S7: Remove the solution in the eggplant-shaped bottle and transfer it to a centrifuge tube. After centrifugation, take out the centrifuge tube and transfer the supernatant to a new centrifuge tube. S8: Filter the liquid in the centrifuge tube containing the supernatant through an aqueous filter membrane to obtain liposomal osimertinib.

2. The method for preparing liposome osimertinib according to claim 1, characterized in that: In the step S1, the amount of the phospholipid is 15 mg, the amount of the cholesterol is 3 mg, and the amount of osimertinib is 3 mg.

3. The method for preparing liposome osimertinib according to claim 1, characterized in that: In the step S2, the amount of anhydrous ethanol used is 1.5 ml.

4. The method for preparing liposome osimertinib according to claim 1, characterized in that: In the step S3, rotary evaporation is performed at 37° C. and 80 rpm / min for 30 minutes.

5. The method for preparing liposome osimertinib according to claim 1, characterized in that: In step S4, the drying time is 6-8 hours.

6. The method for preparing liposome osimertinib according to claim 1, characterized in that: In step S5, the amount of PBS solution used is 3 ml.

7. The method for preparing liposome osimertinib according to claim 1, characterized in that: In step S6, the oscillation frequency of the ultrasonic cleaner is 40 KHz, and the oscillation duration is 15 minutes.

8. The method for preparing liposome osimertinib according to claim 1, characterized in that: In the step S7, centrifugation is performed at 4000 rpm / min for 15 minutes.

9. The method for preparing liposome osimertinib according to claim 1, characterized in that: In the step S8, the working size of the water filter membrane is 0.22 μm.

Citation Information

Patent Citations

  • Molecular targeting drug-entrapped liposome and application of liposome in preparation of drug for treating tumors

    CN111920768A

  • Compositions and methods for delivery of anticancer agents with improved therapeutic index

    US20240041769A1

  • Use of pharmaceutical combination of β-elemene and osimertinib in preparation of Anti-lung cancer medicament

    WO2023227112A1